Evercore ISI upgraded Novocure (NVCR) to Outperform from In Line with a price target of $30, up from $18, heading into the Panova trial readout given what the firm identifies as an “asymmetric risk/reward profile.” PANOVA-3 is a prospective, Phase 3 randomized trial in patients with unresectable, locally advanced pancreatic cancer and assuming about 50% probability for success, peak revenue of greater than 500M and about 30% penetration, the firm sees about 50% upside to shares in a base case, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCR:
- Novocure upgraded to Outperform from In Line at Evercore ISI
- Novocure announces FDA approval of new head flexible electrode transducer arrays
- Novocure participates in a conference call with JPMorgan
- Novocure’s Q3 2024 Results Highlight Growth and Innovation
- NovoCure’s Strong Q3 and Leadership Changes in 2024
Questions or Comments about the article? Write to editor@tipranks.com